#CMOncologyNews?is a biweekly newsletter that focuses on the latest developments in the field of oncology. The newsletter provides updates on clinical trials, new treatments, and emerging technologies in cancer care. It is designed for oncologists, researchers, and healthcare professionals who want to stay up-to-date with the latest trends and insights in oncology.
-
Rapport Therapeutics
have raised $150 million in their Series B funding round. The company will use funds to advance their ongoing clinical programs in seizure and psychiatric disorders, and to expand their pipeline by harnessing their unique capability to leverage receptor-associated proteins for precision neuromedicine.
-
ExcepGen
have emerged from stealth mode and raised $14 million in their Seed funding round. The company plan to use this new funding to prove out the value of our technology in different therapeutic spaces.
-
Tango Therapeutics
have raised $80 million in a private placement financing round. This funding will strengthen their balance sheet as they plan to initiate a fourth clinical trial in 2024.
-
Fore Biotherapeutics
have raised $75 million in their Series D financing round. These funds will be used to accelerate the development of plixorafenib, the company’s novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations.
The Latest in Oncology News:
-
礼来
's highly selective and potent RET kinase inhibitor for advanced medullary thyroid cancer (MTC) has demonstrated superior progression-free survival (PFS) compared to approved multikinase inhibitors. The Phase III study LIBRETTO-531 enrolled 291 patients and is the first randomised trial to compare the safety and efficacy of a highly selective RET-kinase inhibitor with multikinase inhibitors in this patient population.
-
Georgiamune Inc.
have announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-122, a dual-functioning monoclonal antibody. Also, the company successfully completed a $75M Series A financing, positioning Georgiamune as a promising new biotechnology company in the fields of oncology and autoimmune diseases.
-
Elevation Oncology
announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumours likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers.
- Chief Medical Officer - Boston
- Principal Scientist (Medicinal Chemistry) x2 - Boston
- Director of Toxicology - San Diego
- Head of Translational Science - Seattle
- Board Advisor - USA
Do you have any thoughts, or news to share? Join the conversation on LinkedIn by following the hashtag?#CMOncologyNews.
If you're looking to add exceptional talent to your team or seeking new opportunities in the industry, please feel free to reach out to me. As a head-hunter specializing in the Oncology industry, I partner with leading drug discovery companies to help them attract and retain top talent globally. Drop me a message and let's catch up.
